Pharmac has included the weight-loss drug Wegovy in its future funding list, with eligibility based on BMI and comorbidities, amid concerns over cost and effectiveness.
Stacked weekly counts; colour by lean. “n/a” covers government and iwi-Māori sources where lean isn't applicable.
How this topic has been named, week by week. A new alias winning out is usually a framing shift.
How the news corpus has covered this same topic over the last 12 weeks. 3 articles from RNZ, Stuff, NZ Herald, ODT, 1News, Newsroom and The Spinoff. Click through to the press view for the full panel.
Up to 12 framings spread across orientations. Each framing is a short phrase the topic extractor generated to characterise the piece's stance — not a quote from the source. Click through to read the original.
private cost burdens for vulnerable groups
Can Wegovy move the needle on NZ’s obesity crisis, or simply treat its symptoms?cost barriers undermine equitable access
A pill helps you keep weight off after you come off weight-loss jabs – new studySocial-media signal on the same topic, drawn from the social lens. Engagement is likes + 2×shares + 3×replies, the same weighting used across the digest cards. View on /social →
Spotted something wrong on this page? Report a correction.
